This week, 11 biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Stemline Therapeutics, Inc. (STML) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. For more information, get Portfolio Grader’s complete analysis of STML stock.
Pharmacyclics, Inc. (PCYC) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
Acorda Therapeutics, Inc. (ACOR) shows solid improvement this week. The company’s rating rises from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc. (NWBO) earns a B this week, jumping up from last week’s grade of C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
Chimerix, Inc.’s (CMRX) ratings are looking better this week, moving up to an A from last week’s B. For more information, get Portfolio Grader’s complete analysis of CMRX stock.
MediciNova, Inc. (MNOV) is seeing ratings go up from a B last week to an A this week. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
This is a strong week for BioMarin Pharmaceutical (BMRN). The company’s rating climbs to B from the previous week’s C. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) gets a higher grade this week, advancing from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
The rating of Receptos, Inc. (RCPT) moves up this week, rising from a B to an A. For more information, get Portfolio Grader’s complete analysis of RCPT stock.
Ambit Biosciences Corp. (AMBI) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
This week, Amgen’s (AMGN) ratings are up from a B last week to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
